Post-earnings recap
Reported
Wed, Feb 3, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report showed a significant miss on EPS, which may raise concerns among investors about profitability. However, the stock reacted positively, increasing by 2.21%, likely due to management's optimistic tone about long-term growth and product improvements. Investors may be encouraged by the company's focus on innovation despite current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.23 | N/A | -26.05% |
Overall, management acknowledged the difficulties faced during the quarter but maintained a positive outlook for future growth. They emphasized their commitment to innovation and market expansion.
Management highlighted ongoing challenges but expressed confidence in long-term growth.
They noted improvements in certain product lines despite the current environment.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—